EP3642400B1 - Methods and kits of constructing sequencing library for use in detecting chromosome copy number variation - Google Patents
Methods and kits of constructing sequencing library for use in detecting chromosome copy number variation Download PDFInfo
- Publication number
- EP3642400B1 EP3642400B1 EP17914781.4A EP17914781A EP3642400B1 EP 3642400 B1 EP3642400 B1 EP 3642400B1 EP 17914781 A EP17914781 A EP 17914781A EP 3642400 B1 EP3642400 B1 EP 3642400B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sequencing
- dna
- enzyme
- double
- chromosome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000349 chromosome Anatomy 0.000 title claims description 55
- 238000012163 sequencing technique Methods 0.000 title claims description 52
- 238000000034 method Methods 0.000 title claims description 37
- 108020004414 DNA Proteins 0.000 claims description 77
- 102000004190 Enzymes Human genes 0.000 claims description 41
- 108090000790 Enzymes Proteins 0.000 claims description 41
- 238000006062 fragmentation reaction Methods 0.000 claims description 29
- 238000013467 fragmentation Methods 0.000 claims description 27
- 238000001514 detection method Methods 0.000 claims description 16
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 15
- 229960000643 adenine Drugs 0.000 claims description 15
- 101710163270 Nuclease Proteins 0.000 claims description 14
- 102000004533 Endonucleases Human genes 0.000 claims description 13
- 108010042407 Endonucleases Proteins 0.000 claims description 13
- 238000011049 filling Methods 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 6
- 102000012410 DNA Ligases Human genes 0.000 claims description 4
- 108010061982 DNA Ligases Proteins 0.000 claims description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 4
- 238000012165 high-throughput sequencing Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 108020001778 catalytic domains Proteins 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 102000003960 Ligases Human genes 0.000 claims description 2
- 108090000364 Ligases Proteins 0.000 claims description 2
- 238000012408 PCR amplification Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 28
- 238000010276 construction Methods 0.000 description 14
- 238000007481 next generation sequencing Methods 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 208000036878 aneuploidy Diseases 0.000 description 7
- 231100001075 aneuploidy Toxicity 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 208000031404 Chromosome Aberrations Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 2
- 201000009928 Patau syndrome Diseases 0.000 description 2
- 206010044686 Trisomy 13 Diseases 0.000 description 2
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- UQSHSGIYEQDSBW-UHFFFAOYSA-N 2-aminoethane-1,1,1-triol tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NCC(O)(O)O UQSHSGIYEQDSBW-UHFFFAOYSA-N 0.000 description 1
- 241000251477 Chimaera Species 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000037280 Trisomy Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607265 Vibrio vulnificus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 208000024971 chromosomal disease Diseases 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000011304 droplet digital PCR Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
Definitions
- the present invention relates to methods and kits of constructing a library. More particularly, the present invention relates to methods and kits of constructing a sequencing library for use in detecting abnormality in chromosome copy number.
- abnormality in chromosome number accounts for a great proportion of known abnormal chromosome-related diseases (Nagaoka et al., 2012).
- Abnormality in chromosome number can be characterized not only by changes in number of whole chromosomes (such as chromosome aneuploidy), but also by copy number variation (CNV) of certain fragments in certain chromosome (such as chromosome microdeletion microduplication syndrome).
- CNV copy number variation
- diseases caused by chromosome abnormality usually has high incidence, result in serious harm and lack effective treatment, it is important to detect accurately whether the copy number of chromosome is abnormal by technical means.
- the FISH technique which started in late 1980s, combines cytogenetics, immunology and molecular biology, and has well application in clinical study for detecting target chromosome aneuploidy and structure abnormality.
- the design of specific probe in this technique is limited by the information obtained from the target region, thus only limited information about the chromosome can be obtained.
- CMA chromosome microarray analysis
- NGS next generation sequencing
- the object of the present application is to provide a PCR-free method and kit of constructing a sequencing library for use in detecting variation in chromosome copy number, which overcomes the disadvantages of conventional methods for detecting the chromosome copy number variation in terms of resolution, coverage on the whole genome, throughput and cost, while addressing the problem of PCR amplification bias resulted in NGS library construction.
- Chromosome aneuploidy and chromosome microdeletion microduplication syndrome can be screened and diagnosed by using the method and kit of the present application to detect the chromosome copy number variation in a sample to be tested.
- the present application provides a method of constructing a sequencing library for use in detecting chromosome copy number variation, which mainly comprises the following steps:
- the start amount of DNA to be tested preferably is 10-260ng.
- a suitable total amount of a library must not be less than 2fmol to meet the requirement of sequencing.
- the inventors have found a preferable start amount of DNA to be tested of 10-260ng. If the amount is too low, the concentration of the obtained sequencing library will be not high enough to obtain effective sequencing data. On the other hand, if the amount is too high, the random fragmentation of DNAs to be tested will be inadequate. Thus, part of the DNAs to be tested still maintains its form of long fragment due to failure in fragmentation, and this part of DNAs cannot be effectively sequenced, which will have an impact on the concentration of the finally obtained library as well as the accuracy of its sequencing (see Example 2).
- the double-strand DNA fragmentation enzyme is an enzyme mixture of a nonspecific notch nuclease and a T7 endonuclease mutant.
- the nonspecific notch nuclease is a nuclease derived from Vibrio such as Vibrio vulnificus (Vvn), wherein said nuclease is wild-type or a mutant thereof.
- the T7 endonuclease mutant is a T7 endonuclease having a mutation or mutations for example in the bridging region of two catalytic domains as disclosed in U.S. publication No. 2007-0042379 .
- the double-strand DNA fragmentation enzyme comprising a nonspecific notch nuclease and a T7 endonuclease mutant is known to one skilled in the art, for example, as those disclosed in the patent publication CN102301009A .
- the unit ratio between the nonspecific notch nuclease and the T7 endonuclease mutant is less than 1:200, for example less than 1:100 or less than 1:10. The range thereof may be 1:2-1:200. Most preferably, the unit ratio between the nonspecific notch nuclease and the T7 endonuclease mutant is 1:200.
- One unit of T7 endonuclease mutant is defined as the amount of enzyme required to convert 90% of 2 ⁇ g of the linear-nicked 2.44 kb dsDNA into two fragments (1.37 kb and 1.07 kb) at 37°C for 1 hour.
- One unit of Vvn nuclease and mutants thereof is defined as the amount of enzyme required to release 1 A 260 unit of acid soluble oligonucleotides in 30 min at 37°C.
- the optimal incubation time for the DNA fragmentation reaction can be determined according to whether DNA has greater than 60% GC (high GC amount), 40-60% GC (standard GC amount) or less than 40% GC (low GC amount).
- the incubation time typically may be in a range of 5-120min, for example 15-60min.
- the temperature of the DNA fragmentation reaction is 35-40 °C, most preferably 37°C.
- the random fragmentation of DNA to be detected is occurred in the presence of Buffer I, wherein said Buffer I mainly comprise 20mM trihydroxymethyl aminomethane-HCl (Tris-HCl), 15mM magnesium chloride (MgCl 2 ), 50mM sodium chloride (NaCl), 0.1mg/ml bovine serum albumin (BSA), and 0.15% Triton.
- Buffer I mainly comprise 20mM trihydroxymethyl aminomethane-HCl (Tris-HCl), 15mM magnesium chloride (MgCl 2 ), 50mM sodium chloride (NaCl), 0.1mg/ml bovine serum albumin (BSA), and 0.15% Triton.
- Buffer I mainly comprise 20mM trihydroxymethyl aminomethane-HCl (Tris-HCl), 15mM magnesium chloride (MgCl 2 ), 50mM sodium chloride (NaCl), 0.1mg/ml bovine serum albumin (BSA), and 0.15% Triton.
- step (1) there is a step of inactivating the double-strand DNA fragmentation enzymes between step (1) and step (2).
- the inactivation of the double-strand DNA fragmentation enzymes is carried out in a water bath at 60-70°C, such as 65°C for 10-13min, preferably in the presence of a buffer II, which comprises mainly 50mM NaCl, 10mM Tris-HCl, 10mM MgCl 2 and 1mM dithiothreitol(DTT).
- buffer II provides suitable ion concentrations for the inactivation of the enzyme, and also provides a suitable environment for the following reactions of end-filling and poly-adenine addition at 3'-end.
- any enzymes suitable for end-filling known by one skilled in the art can be used for end-filling of the present application.
- examples of such enzymes include but not limited to T4 DNA polymerase, Klenow enzyme and the like.
- any enzymes suitable for adding poly-adenine at 3'-end known by one skilled in the art can be used to add poly-adenine at 3'-end of the DNA.
- examples of such enzymes include but not limited to the Taq enzyme, klenow ex-enzyme (an improved Klenow enzyme without 3'-5' exonuclease activity, New England Biolabs).
- end-filling is carried out simultaneously with the poly-adenine addition, which simplifies the operation steps, saves the cost, while reducing possible contaminations among samples.
- one skilled in the art can determine the incubation time and temperature used in the end-filing and poly-adenine addition at 3'-end as needed by conventional technologies.
- any enzymes suitable for connecting a sequencing linker known by one skilled in the art can be used.
- examples of such enzymes include but not limited to T4 DNA ligase, T7 DNA ligase or their mixtures.
- the sequencing linkers used in the present invention are double-strand sequencing linkers matched to the sequencing platform, and can be selected by one skilled in the art according to conventional techniques.
- the connecting step is carried out in the presence of buffer III, which mainly comprises 50mM NaCl, 10mM Tris-HCl, 10mM MgCl 2 and 0.1% bovine serum albumin (BSA).
- buffer III which mainly comprises 50mM NaCl, 10mM Tris-HCl, 10mM MgCl 2 and 0.1% bovine serum albumin (BSA).
- BSA bovine serum albumin
- a commercial kit of any reagents known by one skilled in the art can be used to purify the sequencing library obtained according to the construction method of the present application prior to sequencing.
- the obtained sequencing library is suitable for the second generation high-throughput sequencing platforms, such as HiSeq, MiSeq, MiniSeq, MySeq, NovaSeq sequencing platforms from Illumina, and PGM and Proton sequencing platforms from Thermo Fisher, and the like.
- the present invention provides a kit for constructing a sequencing library for use in detecting chromosome copy number variation, comprising: double-strand DNA fragmentation enzymes, buffer I, enzymes suitable for DNA end-filling, enzymes suitable for adding poly-adenine at 3' end, sequencing linkers, ligase and buffer III, wherein the DNA fragmentation, DNA end-filling and addition of poly-adenine at 3' end are carried out in a single reaction tube.
- the kit may further comprise buffer II.
- the composition of buffer I, II and III are as described above.
- the kit according to the present invention further comprises a DNA sample used as a negative control, which is a normal DNA sample does not comprise chromosome copy number variation.
- the method for constructing a library according to the present invention basically is completed by enzymatic reactions.
- the properties of easy inactivation of enzymes and different reacting temperatures in different steps make it possible to sequentially and continuously carrying out the three steps of DNA random fragmentation, end-filling and poly-adenine addition at 3'-end in a single reaction tube without DNA purification between the steps.
- the construction method according to the present invention can be practiced in a single reaction tube, it also avoids sample loss and reduces sample contamination resulted from DNA sample transfer. Further, as only a small number of reagents are involved, the construction method and kit of the present application allow a relatively simple operation procedure, and is easy for practice.
- the construction method according to the present application does not comprise a PCR step, thus avoiding amplification bias brought by the PCR operation per se, thereby improving the accuracy of the detection.
- the construction method and kit according to the present application can detect a sample DNA as less as lOng accurately. That is, the initial amount of DNA sample required is low.
- Example 1 library construction according to the present invention and its use in DNA sequencing
- This example detected the chromosome aneuploidy abnormality exemplified by Patau syndrome (T13) and chromosome microdeletion exemplified by chromosome 22q11.2 microdeletion syndrome, using the method and kit for constructing a a sequencing library for use in detecting chromosome copy number variation according to the present invention.
- the Patau syndrome is a common trisomy syndrome, and is due to the presence of a third copy of chromosome 13.
- the chromosome 22q11.2 microdeletion syndrome is a clinical syndrome resulted from 22q11.21-q11.23 microdeletion in chromosome 22, and it is one of the most common microdeletion syndromes.
- the sample DNAs are detected according to the following method. 1. determining concentration: the concentration of DNA samples to be tested was measured by Qubit florometer, and the initial amounts of DNA samples were adjusted preferably as 10-260 ng. 2. constructing a library: a sequencing library was constructed according to the method of the present application, which specifically comprises the following steps: (1) preparing a reaction mixture on ice using DNA samples to be tested and a negative control (a normal DNA sample) as indicated in Table 1. Table 1: Reagents Amount DNA sample lOng Double-stranded DNA fragmentation enzyme 1 ⁇ l Buffer I 1 ⁇ l EB buffer add to 10 ⁇ l After thorough mixing, the reaction mixture is incubated at 37°C for 10 min.
- reaction mixture was transferred onto ice, added with 7 ⁇ l buffer II, and incubated for 10min at 65 °C after mixing thoroughly, so as to inactive the double-stranded DNA fragmentation enzyme.
- the reaction mixture was transferred onto ice, added with 1.5 ⁇ l T4 DNA polymerase and 1.5 ⁇ l Taq enzyme, and then added to 50 ⁇ l using the EB buffer. After thorough mixing, the reaction mixture was centrifuged for 5s at room temperature instantly, and bubbles were removed by slight flicks. Then, the reaction mixture was placed in a normal PCR machine (or a thermo metal bath) to carry out the following incubation steps: 20min at 37°C, followed by 20 min at 72°C, and finally 5 min at 4 °C.
- the reaction mixture was placed in a normal PCR machine (or a thermo metal bath) to carry out the following incubation steps: 15min at 20°C, followed by 10 min at 65°C, and finally 5 min at 4 °C.
- the sequencing library was obtained after the incubation.
- 3. purifying the library and sequencing the obtained sequencing library was purified using a purification kit from Hangzhou Berry Genomics Diagnostic Technology Ltd. (Lot No.: R0022), and the total amount is not less than 2fmol. Then, the purified sequencing library was loaded and sequenced on a NextSeq CN500 sequencing machine (National Medical Instrument Registration No.: 20153400460) according to the instructions of the manufactures.
- analyzing the sequencing results the sequencing results were aligned with the human genome reference sequences. The detection results of chromosome copy number in samples to be tested and in normal samples are presented in Figures 2 and 3 .
- ratio indicated in the Y-axis log 2 (ratio) refers to the ratio between the copy number of the detected region and 2 (i.e., diploid), and the X-axis represents the whole chromosome region.
- the whole chromosome region was evenly divided into lots of bins, wherein the log 2 (ratio) value of each bin corresponds to a single dot, and the distribution of all dots was used to obtain a trend line (the grey line).
- the black line in Figures 2 and 3 represents location of centromere in the chromosome, and separates the chromosome into a short arm and a long arm.
- Figure 2 shows the detection results of copy number in the chromosome 13 region of a DNA sample to be tested (A) and a normal sample (B).
- the DNA sample to be tested was detected by SNP-array, which confirmed the presence of three copies of chromosome 13 long arm. In other words, the detection results obtained using the library construction method and kit of the present invention are consistent with the clinical detection results.
- the inventors also used the method and kit of the present invention to construct second libraries for a second DNA sample to be tested and a normal sample and then performed sequencing as indicated above.
- the DNA sample to be tested was detected by SNP-array, which confirmed the presence of microdeletion in 22q11.2 region of chromosome 22.
- the detection results obtained using the library construction method and kit of the present invention are consistent with the clinical detection results.
- This example shows that the library construction method and kit of the present invention can be used for constructing a sequencing library which allows the accurate detection of chromosome copy number variation by high throughput sequencing.
- the DNA initial amount used for preparing a sequencing library preferably is 10-260n1.812g.
Description
- The present invention relates to methods and kits of constructing a library. More particularly, the present invention relates to methods and kits of constructing a sequencing library for use in detecting abnormality in chromosome copy number.
- It has been reported that abnormality in chromosome number accounts for a great proportion of known abnormal chromosome-related diseases (Nagaoka et al., 2012). Abnormality in chromosome number can be characterized not only by changes in number of whole chromosomes (such as chromosome aneuploidy), but also by copy number variation (CNV) of certain fragments in certain chromosome (such as chromosome microdeletion microduplication syndrome). As diseases caused by chromosome abnormality usually has high incidence, result in serious harm and lack effective treatment, it is important to detect accurately whether the copy number of chromosome is abnormal by technical means.
- Currently, conventional karyotyping in combination with fluorescence in situ hybridization (FISH) or chromosome microarray analysis (CMA, such as aCGH and SNP-array) are main techniques and standards used in clinical for detecting chromosome copy number variation (Nord et al., 2015). Karyotyping with high resolution, which was established in 1970s (Yunis, 1978; Trask, 2002), is still the golden standard in the detection of chromosome abnormality including chromosome aneuploidy, equilibrium or non-equilibrium structural rearrangement, deletion/duplication of large fragments, chimaera and the like. However, its resolution is relatively low (around 5Mb), and is unable to detect copy number variation of small fragments of a chromosome with clinical significance. On the other hand, the FISH technique, which started in late 1980s, combines cytogenetics, immunology and molecular biology, and has well application in clinical study for detecting target chromosome aneuploidy and structure abnormality. However, the design of specific probe in this technique is limited by the information obtained from the target region, thus only limited information about the chromosome can be obtained. Recently developed chromosome microarray analysis (CMA) is a molecular karyotyping technique for high throughput detection of genomic DNA copy number variation, wherein relatively matured comparative genomic hybridization (aCGH) and single nucleotide polymorphism (SNP) array both are CMA techniques (Manning and Hudgins, 2010). Although CMA has a high resolution compared with conventional karyotyping (Breman et al., 2012), in clinical application, the microarray chip must be customized according to detailed chromosomal abnormalities and related clinical information in the public database. Thus, it is insufficient for the detection of certain microdelection and/or microduplication that is rare or not included in the database. In addition, the current CMA technology is difficult and has a high cost, thereby limiting its broad application in less developed areas. Thus, in order to investigating and diagnosing chromosomal diseases more widely, there is a need for an economical and simple method of detecting chromosome copy number variation accurately while ensuring the detection throughput and resolution.
- In recent years, the increasingly mature next generation sequencing (NGS) technology has been widely used in clinical studies due to its prominent advantages like high throughput, high accuracy, high sensitivity, high automation and low operation cost (Xuan et al., 2013). The most common principle employed in the detection of CNV by NGS is based on read-depth, i.e., determining the presence of CNV in certain fragments by calculating and comparing the depth of said fragments with the pre-calibrated theoretical value. This method applies to both single-end sequencing and paired-end sequencing (Yoon et al., 2009; Mason-Suares et al., 2016). During the construction of a NGS library, a standard PCR is often used to amplify random fragments, while the amplification bias brought by the PCR method will inevitably affect the accuracy of the obtained data (van Dijk et al., 2014; Head et al., 2014; Goodwin et al., 2016). Thus, it is critical to establish a simple PCR-free library construction method, thus to improve the detection accuracy of chromosome aneuploidy, in particular CNV.
- Further background art is described in
WO 2015/117040 A1 ,WO 2012/024658 A2 , Roche, "KAPA HYPER PLUS Integrated Fragmentation and Library Preparation Solution Tunable and Reproducible Fragmentation", 2015, and Louise Aigrain et al., "Quantitation of next generation sequencing library preparation protocol efficiencies using droplet digital PCR assays - a systematic comparison of DNA library preparation kits for Illumina sequencing", 2016. - The object of the present application is to provide a PCR-free method and kit of constructing a sequencing library for use in detecting variation in chromosome copy number, which overcomes the disadvantages of conventional methods for detecting the chromosome copy number variation in terms of resolution, coverage on the whole genome, throughput and cost, while addressing the problem of PCR amplification bias resulted in NGS library construction. Chromosome aneuploidy and chromosome microdeletion microduplication syndrome can be screened and diagnosed by using the method and kit of the present application to detect the chromosome copy number variation in a sample to be tested.
- Thus, in a first aspect, the present application provides a method of constructing a sequencing library for use in detecting chromosome copy number variation, which mainly comprises the following steps:
- (1) subjecting DNAs to be tested to random fragmentation by a double-strand DNA fragmentation enzyme;
- (2) end-filling and adding poly-adenine tail at the 3' end of the fragmented DNAs;
- (3) connecting the end-filled DNAs having a 3' end poly-adenine tail with linkers to obtain connected products;
- (4) purifying the connected products to obtain the sequencing library;
- In one embodiment, the start amount of DNA to be tested preferably is 10-260ng. One skilled in the art knows that a suitable total amount of a library must not be less than 2fmol to meet the requirement of sequencing. Thus, to ensure the total amount of the constructed library to be at least equal to 2fmol, the inventors have found a preferable start amount of DNA to be tested of 10-260ng. If the amount is too low, the concentration of the obtained sequencing library will be not high enough to obtain effective sequencing data. On the other hand, if the amount is too high, the random fragmentation of DNAs to be tested will be inadequate. Thus, part of the DNAs to be tested still maintains its form of long fragment due to failure in fragmentation, and this part of DNAs cannot be effectively sequenced, which will have an impact on the concentration of the finally obtained library as well as the accuracy of its sequencing (see Example 2).
- In one embodiment, the double-strand DNA fragmentation enzyme is an enzyme mixture of a nonspecific notch nuclease and a T7 endonuclease mutant. In particular, the nonspecific notch nuclease is a nuclease derived from Vibrio such as Vibrio vulnificus (Vvn), wherein said nuclease is wild-type or a mutant thereof. The T7 endonuclease mutant is a T7 endonuclease having a mutation or mutations for example in the bridging region of two catalytic domains as disclosed in
U.S. publication No. 2007-0042379 . In one embodiment, the double-strand DNA fragmentation enzyme comprising a nonspecific notch nuclease and a T7 endonuclease mutant is known to one skilled in the art, for example, as those disclosed in the patent publicationCN102301009A . - In one embodiment, the unit ratio between the nonspecific notch nuclease and the T7 endonuclease mutant is less than 1:200, for example less than 1:100 or less than 1:10. The range thereof may be 1:2-1:200. Most preferably, the unit ratio between the nonspecific notch nuclease and the T7 endonuclease mutant is 1:200. One unit of T7 endonuclease mutant is defined as the amount of enzyme required to convert 90% of 2 µg of the linear-nicked 2.44 kb dsDNA into two fragments (1.37 kb and 1.07 kb) at 37°C for 1 hour. One unit of Vvn nuclease and mutants thereof is defined as the amount of enzyme required to release 1 A260 unit of acid soluble oligonucleotides in 30 min at 37°C.
- In one embodiment, the optimal incubation time for the DNA fragmentation reaction can be determined according to whether DNA has greater than 60% GC (high GC amount), 40-60% GC (standard GC amount) or less than 40% GC (low GC amount). For example, the incubation time typically may be in a range of 5-120min, for example 15-60min.
- In one embodiment, the temperature of the DNA fragmentation reaction is 35-40 °C, most preferably 37°C.
- In one embodiment, the random fragmentation of DNA to be detected is occurred in the presence of Buffer I, wherein said Buffer I mainly comprise 20mM trihydroxymethyl aminomethane-HCl (Tris-HCl), 15mM magnesium chloride (MgCl2), 50mM sodium chloride (NaCl), 0.1mg/ml bovine serum albumin (BSA), and 0.15% Triton. The presence of Buffer I provide suitable reaction environment for the DNA fragmentation while maintaining the stability of the DNA fragmentation enzymes and improving the enzymatic activity thereof.
- In one embodiment, there is a step of inactivating the double-strand DNA fragmentation enzymes between step (1) and step (2). The inactivation of the double-strand DNA fragmentation enzymes is carried out in a water bath at 60-70°C, such as 65°C for 10-13min, preferably in the presence of a buffer II, which comprises mainly 50mM NaCl, 10mM Tris-HCl, 10mM MgCl2 and 1mM dithiothreitol(DTT). The presence of buffer II provides suitable ion concentrations for the inactivation of the enzyme, and also provides a suitable environment for the following reactions of end-filling and poly-adenine addition at 3'-end.
- In one embodiment, any enzymes suitable for end-filling known by one skilled in the art can be used for end-filling of the present application. Examples of such enzymes include but not limited to T4 DNA polymerase, Klenow enzyme and the like. In one embodiment, any enzymes suitable for adding poly-adenine at 3'-end known by one skilled in the art can be used to add poly-adenine at 3'-end of the DNA. Examples of such enzymes include but not limited to the Taq enzyme, klenow ex-enzyme (an improved Klenow enzyme without 3'-5' exonuclease activity, New England Biolabs). In the method for constructing a library of the present invention, end-filling is carried out simultaneously with the poly-adenine addition, which simplifies the operation steps, saves the cost, while reducing possible contaminations among samples.
- In one embodiment, one skilled in the art can determine the incubation time and temperature used in the end-filing and poly-adenine addition at 3'-end as needed by conventional technologies.
- In one embodiment, any enzymes suitable for connecting a sequencing linker known by one skilled in the art can be used. Examples of such enzymes include but not limited to T4 DNA ligase, T7 DNA ligase or their mixtures. The sequencing linkers used in the present invention are double-strand sequencing linkers matched to the sequencing platform, and can be selected by one skilled in the art according to conventional techniques. Preferably, the connecting step is carried out in the presence of buffer III, which mainly comprises 50mM NaCl, 10mM Tris-HCl, 10mM MgCl2 and 0.1% bovine serum albumin (BSA). The presence of buffer III provides a suitable environment for the connection reaction, and maintains the stability of the enzymes.
- In one embodiment, a commercial kit of any reagents known by one skilled in the art can be used to purify the sequencing library obtained according to the construction method of the present application prior to sequencing. The obtained sequencing library is suitable for the second generation high-throughput sequencing platforms, such as HiSeq, MiSeq, MiniSeq, MySeq, NovaSeq sequencing platforms from Illumina, and PGM and Proton sequencing platforms from Thermo Fisher, and the like.
- In a second aspect, the present invention provides a kit for constructing a sequencing library for use in detecting chromosome copy number variation, comprising: double-strand DNA fragmentation enzymes, buffer I, enzymes suitable for DNA end-filling, enzymes suitable for adding poly-adenine at 3' end, sequencing linkers, ligase and buffer III, wherein the DNA fragmentation, DNA end-filling and addition of poly-adenine at 3' end are carried out in a single reaction tube. The kit may further comprise buffer II. The composition of buffer I, II and III are as described above.
- In one embodiment, the kit according to the present invention further comprises a DNA sample used as a negative control, which is a normal DNA sample does not comprise chromosome copy number variation.
- The method for constructing a library according to the present invention basically is completed by enzymatic reactions. The properties of easy inactivation of enzymes and different reacting temperatures in different steps make it possible to sequentially and continuously carrying out the three steps of DNA random fragmentation, end-filling and poly-adenine addition at 3'-end in a single reaction tube without DNA purification between the steps. As the construction method according to the present invention can be practiced in a single reaction tube, it also avoids sample loss and reduces sample contamination resulted from DNA sample transfer. Further, as only a small number of reagents are involved, the construction method and kit of the present application allow a relatively simple operation procedure, and is easy for practice. Moreover, the construction method according to the present application does not comprise a PCR step, thus avoiding amplification bias brought by the PCR operation per se, thereby improving the accuracy of the detection. Finally, the construction method and kit according to the present application can detect a sample DNA as less as lOng accurately. That is, the initial amount of DNA sample required is low.
-
-
Figure 1 is a diagram illustrating the method for constructing a library according to the present invention. -
Figure 2 shows the sequencing results of a DNA sample to be tested (A) and a control normal sample (B) using libraries constructed according to the method of the present invention. -
Figure 3 shows the sequencing results of a second DNA sample to be tested (A) and a control normal sample (B) using libraries constructed according to the method of the present invention. - This example detected the chromosome aneuploidy abnormality exemplified by Patau syndrome (T13) and chromosome microdeletion exemplified by chromosome 22q11.2 microdeletion syndrome, using the method and kit for constructing a a sequencing library for use in detecting chromosome copy number variation according to the present invention. Specifically, the Patau syndrome is a common trisomy syndrome, and is due to the presence of a third copy of chromosome 13. The chromosome 22q11.2 microdeletion syndrome is a clinical syndrome resulted from 22q11.21-q11.23 microdeletion in chromosome 22, and it is one of the most common microdeletion syndromes.
- The sample DNAs are detected according to the following method.
1. determining concentration: the concentration of DNA samples to be tested was measured by Qubit florometer, and the initial amounts of DNA samples were adjusted preferably as 10-260 ng.
2. constructing a library: a sequencing library was constructed according to the method of the present application, which specifically comprises the following steps:
(1) preparing a reaction mixture on ice using DNA samples to be tested and a negative control (a normal DNA sample) as indicated in Table 1.Table 1: Reagents Amount DNA sample lOng Double-stranded DNA fragmentation enzyme 1µl Buffer I 1µl EB buffer add to 10µl
(2) The reaction mixture was transferred onto ice, added with 7µl buffer II, and incubated for 10min at 65 °C after mixing thoroughly, so as to inactive the double-stranded DNA fragmentation enzyme.
(3) The reaction mixture was transferred onto ice, added with 1.5µl T4 DNA polymerase and 1.5µl Taq enzyme, and then added to 50µl using the EB buffer. After thorough mixing, the reaction mixture was centrifuged for 5s at room temperature instantly, and bubbles were removed by slight flicks. Then, the reaction mixture was placed in a normal PCR machine (or a thermo metal bath) to carry out the following incubation steps: 20min at 37°C, followed by 20 min at 72°C, and finally 5 min at 4 °C.
(4) After incubation in the PCR machine (or a thermo metal bath), the reaction mixture was took out and placed on ice. Meanwhile, a pre-mixture is prepared according to Table 2.Table 2: Reagents Amount Buffer III 25µl T4 DNA ligase 1µl
3. purifying the library and sequencing: the obtained sequencing library was purified using a purification kit from Hangzhou Berry Genomics Diagnostic Technology Ltd. (Lot No.: R0022), and the total amount is not less than 2fmol. Then, the purified sequencing library was loaded and sequenced on a NextSeq CN500 sequencing machine (National Medical Instrument Registration No.: 20153400460) according to the instructions of the manufactures.
4. analyzing the sequencing results: the sequencing results were aligned with the human genome reference sequences. The detection results of chromosome copy number in samples to be tested and in normal samples are presented inFigures 2 and3 . - In
Figures 2 and3 , "ration" indicated in the Y-axis log2(ratio) refers to the ratio between the copy number of the detected region and 2 (i.e., diploid), and the X-axis represents the whole chromosome region. The whole chromosome region was evenly divided into lots of bins, wherein the log2(ratio) value of each bin corresponds to a single dot, and the distribution of all dots was used to obtain a trend line (the grey line). The black line inFigures 2 and3 represents location of centromere in the chromosome, and separates the chromosome into a short arm and a long arm. As there are no reference sequences for the short arms of chromosomes 13 and 22 in the current human genome reference sequences that can be used for data analysis, the sequencing results related to the short arms of chromosomes 13 and 22 cannot be analyzed, resulting in the absence of corresponding log2(ratio) values in these regions. - Specifically,
Figure 2 shows the detection results of copy number in the chromosome 13 region of a DNA sample to be tested (A) and a normal sample (B). It is clear that for the DNA sample to be tested, the log2(ratio) value of the long arm of chromosome 13 is around 0.585 (=log21.5), indicating that at least there are three copies for long arm part of the chromosome 13. That is, the DNA sample to be tested has Patau Sydrome (T13). Meanwhile, for the normal sample, the log2(ratio) value of the long arm of chromosome 13 is 0(=log21), indicating that the chromosome 13 has only two copies. The DNA sample to be tested was detected by SNP-array, which confirmed the presence of three copies of chromosome 13 long arm. In other words, the detection results obtained using the library construction method and kit of the present invention are consistent with the clinical detection results. - The inventors also used the method and kit of the present invention to construct second libraries for a second DNA sample to be tested and a normal sample and then performed sequencing as indicated above. The results are shown in
Figure 3 . It is clear that for this DNA sample to be tested, the log2(ratio) value of chromosome 22 in the 20M region is around -1(=log20.5), indicating that this region has only one copy. When aligned to the human genome reference sequences, this region with only one copy corresponds to the 22q11.21-q11.23 region. Thus, the DNA sample to be tested was confirmed to have a chromosome 22q11.2 microdeletion syndrome. Meanwhile, for the normal sample, the log2(ratio) value of the long arm of chromosome 22 is 0(=log21), indicating that there is no deletion in 22q11.2 region of chromosome 22. The DNA sample to be tested was detected by SNP-array, which confirmed the presence of microdeletion in 22q11.2 region of chromosome 22. In other words, the detection results obtained using the library construction method and kit of the present invention are consistent with the clinical detection results. - This example shows that the library construction method and kit of the present invention can be used for constructing a sequencing library which allows the accurate detection of chromosome copy number variation by high throughput sequencing.
- Samples with various initial amounts of DNA were used to prepare sequencing libraries according to the library construction and purification method of Example 1, and the total amount of obtained libraries were measured. The results are represented in Table 3.
Table 3: The DNA initial amounts and the total amounts of finally obtained libraries DNA initial amount (ng) Total amount of library (fmol) DNA initial amount (ng) Total amount of library (fmol) <5 0.142 150 2.752 <5 0.2 200 2.348 <5 0.21 200 1.782 <5 0.108 220 2.462 <5 0.129 220 1.758 <5 0.169 240 2.078 5 1.053 240 1.935 5 1.592 260 2.149 10 2.776 260 2.228 10 2.401 280 1.405 50 2.97 280 1.585 50 2.988 290 1.982 100 2.318 290 1.812 100 3.11 300 1.04 150 2.477 300 0.568 -
- Nagaoka SI, Hassold TJ, and Hunt PA. Human aneuploidy: mechanisms and new insights into an age-old problem. Nat. Rev. Genet. 2012, 13: 493e504
- Nord A, Salipante SJ, Pritchard C. Chapter 11 - Copy Number Variant Detection Using Next-Generation Sequencing. Clinical Genomics, 2015 , 8 :165-187
- Yunis J. High-resolution chromosome analysis in clinical medicine. Prog. Clin. Pathol., 1978, 7: 267-288
- Trask BJ. Human cytogenetics: 46 chromosomes, 46 years and counting. Nat. Rev. Genet. 2002, 3: 769e778
- Trask BJ. Fluoresence in situ hybridization: application in cytogenetics and gene mapping. Trends Gnent. 1991, 7:149-154.
- Manning M, and Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet. Med. 2010, 12(11):742-745.
- Breman A, Pursley AN, Hixson P, Bi W, Ward P, Bacino CA, Shaw C, Lupski JR, Beaudet A, Patel A, Cheung SW, Van den Veyver I: Prenatal chromosomal microarray analysis in a diagnostic laboratory : experience with >1000 cases and review of the literature. Prenat. Diagn. 2012, 32: 351e361.
- Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett. 2013, 340(2):284-295.
- Yoon S, Xuan Z, Makarov V, Ye K, Sebat J. Sensitive and accurate detection of copy number variants using read depth of coverage. Genome Res. 2009, 19(9):1586-1592.
- Mason-Suares H, Landry L, Lebo MS. Detecting Copy Number Variation via Next Generation Technology. Curr. Genet. Med. Report. 2016, 4 (3): 1-12.
- van Dijk EL, Jaszczyszyn Y, Thermes C. Library preparation methods for next-generation sequencing: tone down the bias. Exp. Cell Res. 2014, 322(1):12-20.
- Head SR, Komori HK, LaMere SA, Whisenant T, Van Nieuwerburgh F, Salomon DR, Ordoukhanian P1.Library construction for next-generation sequencing: overviews and challenges. Biotechniques. 2014, 56(2):61-64.
- Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. Genet. 2016, 17(6):333-351.
Claims (13)
- A method of rapidly constructing a high throughput sequencing library for detecting chromosome copy number variation, characterized in that, the method comprises the following steps:(1) subjecting DNAs to be tested to random fragmentation by a double-strand DNA fragmentation enzyme;(2) end-filling and adding poly-adenine at the 3' end of the fragmented DNAs;(3) connecting the end-filled DNAs having a 3' end poly-adenine with sequencing linkers to obtain connected products;(4) purifying the connected products to obtain the sequencing library;wherein steps (1)-(3) are performed in a single reaction tube;wherein the DNAs are as less as lOng; andwherein the method does not comprise a step of PCR amplification.
- The method according to claim 1, characterized in that, there is no DNA purification steps among steps (1)-(3).
- The method according to claim 1, characterized in that, there is a step of inactivating the double-strand DNA fragmentation enzymes between the step (1) and step (2).
- The method according to claim 1, characterized in that, the double-strand DNA fragmentation enzyme is an enzyme mixture of a nonspecific notch nuclease and a T7 endonuclease mutant.
- The method according to claim 3, characterized in that, the nonspecific notch nuclease is a Vvn nuclease, and the T7 endonuclease mutant is a T7 endonuclease having a mutation or mutations in the bridging region of two catalytic domains.
- The method according to claim 1, characterized in that, step (2) is carried out by T4 DNA polymerase and Taq enzyme.
- The method according to claim 1, characterized in that, the sequencing linkers are double-strand sequencing linkers matched to sequencing platforms.
- The method according to claim 1, characterized in that, step (3) is carried out by T4 DNA ligase.
- The method according to claim 1, characterized in that, the sequencing library is suitable for the second generation high throughput sequencing platforms.
- A kit for constructing a sequencing library for use in PCR-free detection of chromosome copy number variation, characterized in that, the kit comprises: double-strand DNA fragmentation enzymes and buffer I for DNA fragmentation, enzymes for DNA end-filling, enzymes for adding poly-adenine at 3' end, sequencing linkers, ligase and buffer III for ligation, wherein the DNA fragmentation, DNA end-filling and addition of poly-adenine at 3' end are carried out in a single reaction tube, and wherein the DNAs are as less as lOng, characterized in that, the double-strand DNA fragmentation enzyme is an enzyme mixture of a nonspecific notch nuclease and a T7 endonuclease mutant.
- The kit according to claim 10, characterized in that, the nonspecific notch nuclease is a Vvn nuclease, and the T7 endonuclease mutant is a T7 endonuclease having a mutation or mutations in the bridging region of two catalytic domains.
- The kit according to claim 10, characterized in that, the enzyme for DNA end-filling is T4 DNA polymerase, and the enzyme for adding poly-adenine at 3' end is Taq enzyme.
- The kit according to claim 10, characterized in that, it further comprises buffer II for inactivating the double-strand DNA fragmentation enzymes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710476884.1A CN107217308A (en) | 2017-06-21 | 2017-06-21 | A kind of sequencing library construction method and kit for being used to detect chromosome copies number variation |
PCT/CN2017/115378 WO2018233236A1 (en) | 2017-06-21 | 2017-12-11 | Methods and kits of constructing sequencing library for use in detecting chromosome copy number variation |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3642400A1 EP3642400A1 (en) | 2020-04-29 |
EP3642400A4 EP3642400A4 (en) | 2020-12-16 |
EP3642400B1 true EP3642400B1 (en) | 2022-12-07 |
Family
ID=59949927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17914781.4A Active EP3642400B1 (en) | 2017-06-21 | 2017-12-11 | Methods and kits of constructing sequencing library for use in detecting chromosome copy number variation |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200131507A1 (en) |
EP (1) | EP3642400B1 (en) |
JP (1) | JP2020529219A (en) |
CN (1) | CN107217308A (en) |
WO (1) | WO2018233236A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107217308A (en) * | 2017-06-21 | 2017-09-29 | 北京贝瑞和康生物技术股份有限公司 | A kind of sequencing library construction method and kit for being used to detect chromosome copies number variation |
CN111379032A (en) * | 2018-12-28 | 2020-07-07 | 北京贝瑞和康生物技术有限公司 | Method and kit for constructing sequencing library for simultaneously realizing genome copy number variation detection and gene mutation detection |
CN109797436B (en) * | 2018-12-29 | 2021-10-08 | 阅尔基因技术(苏州)有限公司 | Sequencing library construction method |
CN116144735A (en) * | 2019-08-12 | 2023-05-23 | 深圳市真迈生物科技有限公司 | Nucleic acid sample processing method, sequencing method and kit |
CN111020018B (en) * | 2019-11-28 | 2021-09-14 | 天津金匙医学科技有限公司 | Macrogenomics-based pathogenic microorganism detection method and kit |
CN111763664B (en) * | 2020-06-28 | 2021-03-26 | 江苏康科斯医疗科技有限公司 | Enzyme reaction liquid for constructing sequencing library and application thereof |
CN113667715A (en) * | 2021-08-11 | 2021-11-19 | 广州达安基因股份有限公司 | Construction method and kit for detecting pathogen DNA library in respiratory tract sample |
CN113512766A (en) * | 2021-08-25 | 2021-10-19 | 广州达安基因股份有限公司 | Construction method of DNA next generation sequencing library |
CN114197061A (en) * | 2022-02-17 | 2022-03-18 | 北京贝瑞和康生物技术有限公司 | Method and kit for constructing sequencing library for detecting chromosome copy number variation |
CN114457143A (en) * | 2022-03-16 | 2022-05-10 | 苏州贝康医疗器械有限公司 | Method for constructing CNV detection library and CNV detection method |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005052124A2 (en) * | 2003-11-21 | 2005-06-09 | New England Biolabs, Inc. | Modified dna cleaving enzymes and methods of use |
CN102301009B (en) * | 2009-02-03 | 2015-09-30 | 新英格兰生物实验室公司 | Enzyme is used to produce random ds breakage in DNA |
JP5780971B2 (en) * | 2009-03-09 | 2015-09-16 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | Random double-strand breaks in DNA using enzymes |
US20130203606A1 (en) * | 2010-02-25 | 2013-08-08 | Advanced Liquid Logic Inc | Method of Preparing a Nucleic Acid Library |
WO2012024658A2 (en) | 2010-08-20 | 2012-02-23 | IntegenX, Inc. | Integrated analysis system |
CN102108406B (en) * | 2010-12-20 | 2014-05-21 | 北京贝瑞和康生物技术有限公司 | Kit, device and method for detecting copy number of embryo chromosomes |
CN103080336B (en) * | 2011-05-31 | 2014-06-04 | 北京贝瑞和康生物技术有限公司 | Kits, devices and methods for detecting chromosome copy number of embryo or tumor |
CN103987856B (en) * | 2011-12-17 | 2016-08-24 | 深圳华大基因股份有限公司 | Determine whether genome exists abnormal method and system |
WO2013104106A1 (en) * | 2012-01-10 | 2013-07-18 | 北京贝瑞和康生物技术有限公司 | Method for construction of plasma dna sequencing library and kit thereof |
HUE058149T2 (en) * | 2014-01-31 | 2022-07-28 | Swift Biosciences Inc | Improved methods for processing dna substrates |
CN111748606A (en) * | 2014-06-24 | 2020-10-09 | 北京贝瑞和康医学检验实验室有限公司 | Method and kit for quickly constructing plasma DNA sequencing library |
CN104694654B (en) * | 2015-03-18 | 2018-04-13 | 北京明谛生物医药科技有限公司 | A kind of kit for detecting fetal chromosomal Number Variation |
CN105734048A (en) * | 2016-02-26 | 2016-07-06 | 武汉冰港生物科技有限公司 | PCR-free sequencing library preparation method for genome DNA |
CN106148513A (en) * | 2016-06-22 | 2016-11-23 | 杭州杰毅麦特医疗器械有限公司 | A kind of dissociative DNA library constructing method and test kit |
CN106497920A (en) * | 2016-11-21 | 2017-03-15 | 深圳华大基因研究院 | A kind of library constructing method and test kit for nonsmall-cell lung cancer detection in Gene Mutation |
CN106755337A (en) * | 2016-11-30 | 2017-05-31 | 杭州杰毅麦特医疗器械有限公司 | A kind of cell chromosome analyzes quick banking process and kit |
CN107217308A (en) * | 2017-06-21 | 2017-09-29 | 北京贝瑞和康生物技术股份有限公司 | A kind of sequencing library construction method and kit for being used to detect chromosome copies number variation |
-
2017
- 2017-06-21 CN CN201710476884.1A patent/CN107217308A/en active Pending
- 2017-12-11 JP JP2020520695A patent/JP2020529219A/en active Pending
- 2017-12-11 WO PCT/CN2017/115378 patent/WO2018233236A1/en unknown
- 2017-12-11 US US16/624,873 patent/US20200131507A1/en not_active Abandoned
- 2017-12-11 EP EP17914781.4A patent/EP3642400B1/en active Active
Non-Patent Citations (2)
Title |
---|
LOUISE AIGRAIN ET AL: "Quantitation of next generation sequencing library preparation protocol efficiencies using droplet digital PCR assays - a systematic comparison of DNA library preparation kits for Illumina sequencing", BMC GENOMICS, vol. 17, no. 1, 13 June 2016 (2016-06-13), XP055453168, DOI: 10.1186/s12864-016-2757-4 * |
ROCHE: "KAPA HYPER PLUS Integrated Fragmentation and Library Preparation Solution Tunable and Reproducible Fragmentation", 1 January 2015 (2015-01-01), XP055852189, Retrieved from the Internet <URL:https://www.n-genetics.com/products/1104/1022/13602.pdf> * |
Also Published As
Publication number | Publication date |
---|---|
US20200131507A1 (en) | 2020-04-30 |
WO2018233236A1 (en) | 2018-12-27 |
EP3642400A1 (en) | 2020-04-29 |
JP2020529219A (en) | 2020-10-08 |
CN107217308A (en) | 2017-09-29 |
EP3642400A4 (en) | 2020-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3642400B1 (en) | Methods and kits of constructing sequencing library for use in detecting chromosome copy number variation | |
AU2018214075B2 (en) | Systems and methods for prenatal genetic analysis | |
EP3191604B1 (en) | Methods and compositions for rapid nucleic acid library preparation | |
AU2010242073C1 (en) | Methods and compositions for evaluating genetic markers | |
EP3382037B1 (en) | Methods for determining fraction of fetal nucleic acids in maternal samples | |
US20150017635A1 (en) | Direct Capture, Amplification and Sequencing of Target DNA Using Immobilized Primers | |
EP3402896B1 (en) | Deep sequencing profiling of tumors | |
US20120003657A1 (en) | Targeted sequencing library preparation by genomic dna circularization | |
US20050037388A1 (en) | Method for detecting diseases caused by chromosomal imbalances | |
US20170327868A1 (en) | Blocker based enrichment system and uses thereof | |
US20110091900A1 (en) | Method for determining dna copy number by competitive pcr | |
CN112292459A (en) | Products and methods for nucleic acid detection and quantification | |
US20200277651A1 (en) | Nucleic Acid Preparation and Analysis | |
US20220364173A1 (en) | Methods and systems for detection of nucleic acid modifications | |
EP4127225A1 (en) | A method of detecting structural rearrangements in a genome | |
Moldovan et al. | Multiplex ligation-dependent probe amplification–a short overview | |
US20230295696A1 (en) | Method for loading nucleic acid molecule on solid support | |
Gallardo et al. | Application to Assisted Reproductive of Whole-Genome Treatment Technologies | |
Gallardo et al. | Application of Whole-Genome Technologies to Assisted Reproductive Treatment | |
Mariana et al. | DESENVOLVIMENTO DE UM MÉTODO DE DETEÇÃO DE CNVs ATRAVÉS DE qPCR | |
EP1567540A2 (en) | Cftr allele detection assays | |
Lam et al. | Candidate Screening through High-Density SNP Array | |
NG | By KEVIN L. GUNDERSON, FRANK J. STEEMERS, HONGI REN, PAULINE NG, LIXIN ZHOU, CHAN TSAN, WEIHUA CHANG, DAVE BULLIS, JOE MUSMACKER, CHRISTINE KING, LORI L. LEBRUSKA, DAVID BARKER, ARNOLD OLIPHANT, KENNETH M. KUHN, and RICHARD SHEN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200120 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20201116 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C40B 50/06 20060101AFI20201110BHEP Ipc: C12Q 1/68 20180101ALI20201110BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20211025 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BERRY GENOMICS CO., LTD |
|
INTG | Intention to grant announced |
Effective date: 20220721 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1536345 Country of ref document: AT Kind code of ref document: T Effective date: 20221215 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017064509 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20221207 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230307 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1536345 Country of ref document: AT Kind code of ref document: T Effective date: 20221207 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230308 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230601 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230410 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20221231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221211 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230407 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017064509 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221231 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221211 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221231 |
|
26N | No opposition filed |
Effective date: 20230908 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221231 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231221 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20231221 Year of fee payment: 7 Ref country code: DE Payment date: 20231219 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20171211 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221207 |